Bullous pemphigoid in a patient treated with nivolumab

被引:6
作者
Cuenca-Barrales, Carlos [1 ]
Espadafor-Lopez, Beatriz [2 ]
Martinez-Lopez, Antonio [2 ]
Cancela-Diez, Barbara [3 ]
Ruiz-Villaverde, Ricardo [1 ]
机构
[1] Hosp Univ San Cecilio, Dermatol Dept, Granada, Spain
[2] Hosp Univ Virgen Nieves, Dermatol Dept, Granada, Spain
[3] Hosp Univ San Cecilio, Pharm Unit, Granada, Spain
关键词
IMMUNE CHECKPOINT BLOCKADE;
D O I
10.1111/dth.13030
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
引用
收藏
页数:2
相关论文
共 10 条
[1]   Histopathologic Features of Colitis Due to Immunotherapy With Anti-PD-1 Antibodies [J].
Chen, Jonathan H. ;
Pezhouh, Maryam K. ;
Lauwers, Gregory Y. ;
Masia, Ricard .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2017, 41 (05) :643-654
[2]   Gray-bluish cutaneous pigmentation and ice-pick scars induced by vandetanib therapy [J].
Cuenca-Barrales, Carlos ;
Lopez-Delgado, David ;
Cancela-Diez, Barbara ;
Galvez-Moreno, Marina ;
Ruiz-Villaverde, Ricardo .
INTERNATIONAL JOURNAL OF DERMATOLOGY, 2018, 57 (07) :E33-E34
[3]   Diverse types of dermatologic toxicities from immune checkpoint blockade therapy [J].
Curry, Jonathan L. ;
Tetzlaff, Michael T. ;
Nagarajan, Priyadharsini ;
Drucker, Carol ;
Diab, Adi ;
Hymes, Sharon R. ;
Duvic, Madeleine ;
Hwu, Wen-Jen ;
Wargo, Jennifer A. ;
Torres-Cabala, Carlos A. ;
Rapini, Ronald P. ;
Prieto, Victor G. .
JOURNAL OF CUTANEOUS PATHOLOGY, 2017, 44 (02) :158-176
[4]   A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab [J].
Fessas, Petros ;
Lee, Hassal ;
Ikemizu, Shinji ;
Janowitz, Tobias .
SEMINARS IN ONCOLOGY, 2017, 44 (02) :136-140
[5]   Immune-related adverse events with immune checkpoint blockade: a comprehensive review [J].
Michot, J. M. ;
Bigenwald, C. ;
Champiat, S. ;
Collins, M. ;
Carbonnel, F. ;
Postel-Vinay, S. ;
Berdelou, A. ;
Varga, A. ;
Bahleda, R. ;
Hollebecque, A. ;
Massard, C. ;
Fuerea, A. ;
Ribrag, V. ;
Gazzah, A. ;
Armand, J. P. ;
Amellal, N. ;
Angevin, E. ;
Noel, N. ;
Boutros, C. ;
Mateus, C. ;
Robert, C. ;
Soria, J. C. ;
Marabelle, A. ;
Lambotte, O. .
EUROPEAN JOURNAL OF CANCER, 2016, 54 :139-148
[6]   Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma [J].
Robert, Caroline ;
Ribas, Antoni ;
Hamid, Omid ;
Daud, Adil ;
Wolchok, Jedd D. ;
Joshua, Anthony M. ;
Hwu, Wen-Jen ;
Weber, Jeffrey S. ;
Gangadhar, Tara C. ;
Joseph, Richard W. ;
Dronca, Roxana ;
Patnaik, Amita ;
Zarour, Hassane ;
Kefford, Richard ;
Hersey, Peter ;
Zhang, Jin ;
Anderson, James ;
Diede, Scott J. ;
Ebbinghaus, Scot ;
Hodi, F. Stephen .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1668-+
[7]   Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials [J].
Schadendorf, Dirk ;
Wolchok, Jedd D. ;
Hodi, F. Stephen ;
Chiarion-Sileni, Vanna ;
Gonzalez, Rene ;
Rutkowski, Piotr ;
Grob, Jean-Jacques ;
Cowey, C. Lance ;
Lao, Christopher D. ;
Chesney, Jason ;
Robert, Caroline ;
Grossmann, Kenneth ;
McDermott, David ;
Walker, Dana ;
Bhore, Rafia ;
Larkin, James ;
Postow, Michael A. .
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (34) :3807-+
[8]   Dermatologic complications of anti-PD-1/PD-L1 immune checkpoint antibodies [J].
Sibaud, Vincent ;
Meyer, Nicolas ;
Lamant, Laurence ;
Vigarios, Emmanuelle ;
Mazieres, Julien ;
Delord, Jean Pierre .
CURRENT OPINION IN ONCOLOGY, 2016, 28 (04) :254-263
[9]   Timing of Onset of Adverse Cutaneous Reactions Associated With Programmed Cell Death Protein 1 Inhibitor Therapy [J].
Wang, Leo L. ;
Patel, Gopal ;
Chiesa-Fuxench, Zelma C. ;
McGettigan, Suzanne ;
Schuchter, Lynn ;
Mitchell, Tara C. ;
Ming, Michael E. ;
Chu, Emily Y. .
JAMA DERMATOLOGY, 2018, 154 (09) :1057-1061
[10]   Anti-programmed cell death-1 therapy-associated bullous disorders: a systematic review of the literature [J].
Zhao, Cathy Yunjia ;
Hwang, Shelley Ji Eun ;
Consuegra, Germana ;
Chou, Shaun ;
Fernandez-Penas, Pablo .
MELANOMA RESEARCH, 2018, 28 (06) :491-501